Association of Lifetime Exposure to Glyphosate and Aminomethylphosphonic Acid (AMPA) with Liver Inflammation and Metabolic Syndrome at Young Adulthood: Findings from the CHAMACOS Study - PubMed (original) (raw)

doi: 10.1289/EHP11721. Epub 2023 Mar 1.

Robert B Gunier 1, Stephen Rauch 1, Katherine Kogut 1, Emily R Perito 2 3, Xenia Mendez 1, Charles Limbach 4, Nina Holland 1, Asa Bradman 1 5, Kim G Harley 1, Paul J Mills 6, Ana M Mora 1

Affiliations

Association of Lifetime Exposure to Glyphosate and Aminomethylphosphonic Acid (AMPA) with Liver Inflammation and Metabolic Syndrome at Young Adulthood: Findings from the CHAMACOS Study

Brenda Eskenazi et al. Environ Health Perspect. 2023 Mar.

Abstract

Background: The prevalence of liver disorders and metabolic syndrome has increased among youth. Glyphosate, the most widely used herbicide worldwide, could contribute to the development of these conditions.

Objective: We aimed to assess whether lifetime exposure to glyphosate and its degradation product, aminomethylphosphonic acid (AMPA), is associated with elevated liver transaminases and metabolic syndrome among young adults.

Methods: We conducted a prospective cohort study (n=480 mother-child dyads) and a nested case-control study (n=60 cases with elevated liver transaminases and 91 controls) using data from the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS). We measured glyphosate and AMPA concentrations in urine samples collected during pregnancy and at child ages 5, 14, and 18 y from cases and controls. We calculated glyphosate residue concentrations: [glyphosate + (1.5×AMPA)]. We estimated the amount of agricultural-use glyphosate applied within a 1-km radius of every residence from pregnancy to age 5 y for the full cohort using California Pesticide Use Reporting data. We assessed liver transaminases and metabolic syndrome at 18 y of age.

Results: Urinary AMPA at age 5 y was associated with elevated transaminases [relative risk (RR) per 2-fold increase=1.27, 95% confidence interval (CI): 1.06, 1.53] and metabolic syndrome (RR=2.07, 95% CI: 1.38, 3.11). Urinary AMPA and glyphosate residues at age 14 y were associated with metabolic syndrome [RR=1.80 (95% CI: 1.10, 2.93) and RR=1.88 (95% CI: 1.03, 3.42), respectively]. Overall, a 2-fold increase in urinary AMPA during childhood was associated with a 14% and a 55% increased risk of elevated liver transaminases and metabolic syndrome, respectively. Living near agricultural glyphosate applications during early childhood (birth to 5 y of age) was also associated with metabolic syndrome at age 18 y in the case-control group (RR=1.53, 95% CI: 1.16, 2.02).

Discussion: Childhood exposure to glyphosate and AMPA may increase risk of liver and cardiometabolic disorders in early adulthood, which could lead to more serious diseases later in life. https://doi.org/10.1289/EHP11721.

PubMed Disclaimer

Figures

Figure 1 is a set of one bar graph and four maps. The bar graph titled total glyphosate use (kilogram), plotting kilogram, ranging from 0 to 120000 in increments of 20000 (y-axis) across years, ranging from 2000 to 2018 in increments of 2 (x-axis). The four maps of Monterey County, California, depict the agricultural use of glyphosate in the years 2000, 2008, 2015, 2014, and 2018. The range for glyphosate (kilogram) ranges as 0.1 to 50, 51 to 100, 101 to 250, 251 to 500, 501 to 1000, and 1001 to 1420. The areas highlighted are Castroville, Salinas, Gonzales, Soledad, Greenfield, Monterey, and King city.

Figure 1.

Agricultural use of glyphosate in Monterey County, California, 2000–2018. Note: Sources: Esri, General Bathymetric Chart of the Oceans (GEBCO), National Oceanic and Atmospheric Administration, National Geographic, Garmin, HERE,

Geonames.org

, and other contributors.

References

    1. Sanyaolu A, Okorie C, Qi X, Locke J, Rehman S. 2019. Childhood and adolescent obesity in the United States: a public health concern. Glob Pediatr Health 6:2333794X19891305, PMID: , 10.1177/2333794X19891305. -DOI -PMC -PubMed
    1. Wittcopp C, Conroy R. 2016. Metabolic syndrome in children and adolescents. Pediatr Rev 37(5):193–202, PMID: , 10.1542/pir.2014-0095. -DOI -PubMed
    1. Jeans MR, Ghaddar R, Vandyousefi S, Landry MJ, Gray MJ, Leidy HJ, et al. 2022. Distinct racial and ethnic metabolic syndrome characteristics: a comparative assessment in low-income children 7–10 years of age. Pediatr Obes 17(10):e12925, PMID: , 10.1111/ijpo.12925. -DOI -PubMed
    1. Doycheva I, Watt KD, Alkhouri N. 2017. Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic. Hepatology 65(6):2100–2109, PMID: , 10.1002/hep.29068. -DOI -PubMed
    1. Goyal NP, Schwimmer JB. 2016. The progression and natural history of pediatric nonalcoholic fatty liver disease. Clin Liver Dis 20(2):325–338, PMID: , 10.1016/j.cld.2015.10.003. -DOI -PMC -PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources